Obese children with Moderate to Severe Sleep Apnea would have baseline evaluation of markers of cardiometabolic risk and insulin resistance. Subjects will then use CPAP for 3 months and will return for another blood draw for measurement of the markers for cardiometabolic risk and insulin resistance.
1. Body mass index greater than 95th percentile for age and gender
2. Moderate to severe OSA (as defined by an apnea-hypopnea index [AHI] score of ≥5 events per hour).
Only patients who provide informed assent or consent and also have consent from a parent will be included.
1. Predominant central sleep apnea
2. Type 1 Diabetes
3. Type 2 Diabetes
4. Requires use of supplemental oxygen
5. Active infection, cancer, or chronic inflammatory disorder
6. Use of systemic steroids
7. Simultaneous use of peroxisome proliferator-activated receptor (PPAR)-alpha (e.g., gemfibrozil, fenofibrate) or PPAR-gamma (e.g., rosiglitazone, pioglitazone)
Last updated: 02/25/2013
NCT ID: NCT01403194